Endo International plc (NASDAQ:ENDP) Expected to Post Quarterly Sales of $667.85 Million

Equities analysts predict that Endo International plc (NASDAQ:ENDP) (TSE:ENL) will announce $667.85 million in sales for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Endo International’s earnings. The highest sales estimate is $704.46 million and the lowest is $651.36 million. Endo International reported sales of $634.86 million during the same quarter last year, which would indicate a positive year over year growth rate of 5.2%. The company is expected to issue its next earnings results after the market closes on Thursday, November 4th.

According to Zacks, analysts expect that Endo International will report full-year sales of $2.79 billion for the current financial year, with estimates ranging from $2.74 billion to $2.87 billion. For the next financial year, analysts expect that the firm will report sales of $2.70 billion, with estimates ranging from $2.55 billion to $2.82 billion. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover Endo International.

Endo International (NASDAQ:ENDP) (TSE:ENL) last released its quarterly earnings data on Thursday, August 5th. The company reported $0.65 EPS for the quarter, beating the consensus estimate of $0.48 by $0.17. Endo International had a net margin of 2.46% and a negative return on equity of 94.51%. The business had revenue of $713.83 million during the quarter, compared to the consensus estimate of $657.27 million. During the same quarter in the prior year, the firm earned $0.65 EPS.

A number of research analysts have weighed in on the stock. Zacks Investment Research raised shares of Endo International from a “strong sell” rating to a “hold” rating and set a $3.50 price objective for the company in a report on Monday, October 18th. Royal Bank of Canada dropped their price objective on shares of Endo International from $6.00 to $5.00 and set a “sector perform” rating on the stock in a research report on Monday, August 9th. Finally, Piper Sandler cut shares of Endo International from an “overweight” rating to a “neutral” rating and decreased their price target for the stock from $10.00 to $3.00 in a research note on Tuesday, August 31st. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $6.79.

A number of institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC boosted its position in shares of Endo International by 15.5% in the first quarter. Geode Capital Management LLC now owns 4,105,987 shares of the company’s stock valued at $30,425,000 after acquiring an additional 549,953 shares during the period. Hennion & Walsh Asset Management Inc. acquired a new position in Endo International during the first quarter worth $3,546,000. LSV Asset Management raised its stake in Endo International by 1,928.1% during the second quarter. LSV Asset Management now owns 452,259 shares of the company’s stock worth $2,116,000 after acquiring an additional 429,959 shares in the last quarter. Alpha Paradigm Partners LLC acquired a new position in Endo International during the second quarter worth $1,120,000. Finally, Tudor Investment Corp Et Al raised its stake in Endo International by 179.8% during the second quarter. Tudor Investment Corp Et Al now owns 355,531 shares of the company’s stock worth $1,664,000 after acquiring an additional 228,477 shares in the last quarter. 79.73% of the stock is owned by hedge funds and other institutional investors.

ENDP traded down $0.34 during trading on Tuesday, hitting $4.38. The stock had a trading volume of 7,894,115 shares, compared to its average volume of 6,461,291. Endo International has a twelve month low of $1.94 and a twelve month high of $10.89. The stock has a 50 day simple moving average of $3.14 and a two-hundred day simple moving average of $4.53. The company has a market capitalization of $1.02 billion, a PE ratio of 15.64 and a beta of 1.37.

About Endo International

Endo International Plc operates as a pharmaceutical company. It focuses on developing, manufacturing, and distributing of branded and generic pharmaceutical products. The firm operates through the following segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals and International Pharmaceuticals.

Read More: Do equity income investments outperform growth and income investments?

Get a free copy of the Zacks research report on Endo International (ENDP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.